Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development. Nucleai will present new data demonstrating the power of its new mIF pipeline to correlate spatial features with patient outcomes in colorectal cancer (CRC) at the Society for Immunotherapy of Cancer (SITC) conference in Boston this week.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.